Growth advantage of chronic myeloid leukemia CFU-GM in vitro: Survival to growth factor deprivation, possibly related to autocrine stimulation, is a more common feature than hypersensitivity to GM-CSF/IL3 and is efficiently counteracted by retinoids ± α-interferon

Leukemia

Volumn 15, Issue 3, 2001, Pages 422-429

  Ferrero, D ^a   Foli, C ^a   Giaretta, F ^a   Argentino, C ^a   Rus, C ^a   Pileri, A ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

CML OFU GM; GM CSF; Growth factor deprivation; IL3; Retinoic acid; interferon

Indexed keywords

ALPHAN1 INTERFERON; BCR ABL PROTEIN; CYTOKINE; GROWTH FACTOR; ISOTRETINOIN; MYELOGEN; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 3; RETINOIC ACID; RETINOID;

ARTICLE; AUTOCRINE EFFECT; CELL GROWTH; CELL SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLINICAL FEATURE; COLONY FORMING UNIT GM; CONCENTRATION RESPONSE; CONTROLLED STUDY; CULTURE MEDIUM; DEPLETION; DILUTION; EXPERIMENTAL MODEL; GENE FUSION; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; HYPERSENSITIVITY; IN VITRO STUDY; PRIORITY JOURNAL; PROMYELOCYTE; PURIFICATION; SERUM; STEREOISOMERISM; STROMA;

EID: 0035082867     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2402038     Document Type: Article

References (57)

1. A minute chromosome in human chronic granulocytic leukemia
2. A new consistent chromosomal abnormality in chronic myelogenous leukemia identified by quinacrine fluorescence and Giemsa staining
3. The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene
4. Fused transcript of abl and bcr genes in chronic myelogenous leukemia
5. BCR-ABL oncoproteins bind directly to activators of Ras signalling pathway
6. The protoncogene product p120 CBL and the adaptor proteins CRKL and C-CRK link c-ABL, p190BCR-ABL and p210 BCR-ABL to phosphatidylinositol-3′ kinase pathway
7. Differential complementation of BCR-ABL point mutation with c-MYC
8. Role of c-ABL tyrosine kinase in growth arrest response to DNA damage
9. BCR/ABL induces multiple abnormalities of cytoskeletal function
10. Induction of chronic myeloid leukemia in mice by the p210 BCR/ABL gene of the Philadelphia chromosome
11. Transformation of an interleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific P210 bcr/abl protein
12. Bcr-abl oncogene renders myeloid cell line factor independent: Potential autocrine mechanisms in chronic myeloid leukemia
13. Expression of the chronic myelogenous leukemia-associated P210 bcr/abl oncoprotein in a murine IL-3 dependent myeloid cell line
14. Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia
15. Use of a temperature-sensitive mutant to define the biological effects of p210 BCR/ABL tyrosine kinase on proliferation of a factor dependent murine myeloid cell line
16. Expression of bcr-abl abrogates factor-dependent growth of human hematopoietic M07E cells by an autocrine mechanism
17. Structural and signaling requirements for BCR-ABL-mediated transformation and inhibition of apoptosis
18. Tyrosine phosphorylation of p95Vav in myeloid cells is regulated by GM-CSF, IL-3 and Steel factor and is constitutively increased by p210 BCR/ABL
19. Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by BCR/ABL
20. Bcr-Abl efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor in mice: A novel model for chronic myelogenous leukemia
21. Insensitivity of chronic myeloid leukemia cells to inhibition of growth by prostaglandin E1
22. MCP-1, not MIP-1 alpha, is the endogenous chemokine that cooperates with TGF-beta to inhibit the cycling of primitive normal but not leukemic (CML) progenitors in long-term human marrow cultures
23. Interferon-alpha restores normal beta 1 integrin-mediated inhibition of hematopoietic progenitor proliferation by the marrow microenvironment in chronic myelogenous leukemia
24. Synthesis of granulocyte colony-stimulating factor and its requirement for terminal divisions in chronic myelogenous leukemia
25. Increased circulating colony-stimulating factor-1 in patients with preleukemia, leukemia and lymphoid malignancies
26. Autocrine production and action of IL-3 and granulocyte colony-stimulating factor in chronic myeloid leukemia
27. BCR-ABL accelerates C2-ceramide-induced apoptosis
28. Apoptosis in chronic myeloid leukemia: Normal response by progenitor cells to growth factor deprivation, X-irradiation and glucocorticoids
29. Primary proliferating immature myeloid cells from CML patients are not resistant to induction of apoptosis by DNA damage and growth factor withdrawal
30. Selective hypersensitivity to granulocyte-macrophage colony-stimulating factor by juvenile chronic myeloid leukemia hematopoietic progenitors
31. Immunological separation of two CFU-GM subsets showing different responsiveness to T-cell derived growth factors
32. CD9 antigen on acute non-lymphoid leukemia: Preferential expression by promyelocytic (M3) subtype
33. Role of chemotherapy and GM-CSF on hemopoietic progenitor cell mobilisation in multiple myeloma
34. Expression of CD44 isoforms by highly enriched CD34-positive cells in cord blood, bone marrow and leukaphereses
35. Biological activities of a human pluripotent hemopoietic colony-stimulating factor on normal and leukemic cells
36. Interleukin 1 α regulates hematopoietic activity, a role previously ascribed to hemopoietin 1
37. Limiting dilution assay for the determination of immunocompetent cell frequency
38. In vitro culture studies of blood and marrow cells in chronic myeloid leukemia at different phases of the disease
39. Unregulated proliferation of primitive chronic myeloid leukemia progenitors in the presence of normal marrow adherent cells
40. Stem cell factor as a single agent induces selective proliferation of the Philadelphia chromosome positive fraction of chronic myeloid leukemia CD34(+) cells
41. Long-term marrow culture reveals chromosomally normal hematopoietic progenitor cells in patients with Philadelphia chromosome-positive chronic myelogenous leukemia
42. Selective expansion of primitive normal hematopoietic cells in cytokine-supplemented cultures from patients with chronic myeloid leukemia
43. Phenotypic characterization of normal and CML CD34-positive cells: Only the most primitive CML progenitors include Ph-neg cells
44. Absence of bcr/abl gene in single hemopoietic progenitors in some patients with chronic myelogenous leukemia
45. Growth inhibition of Ph+ progenitor cells from CML patients using the tyrosine kinase inhibitor CGP57148B
46. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
47. In vitro effect of retinoic acid on normal and chronic myeloid leukemia granulopoiesis
48. All-trans retinoic acid combined with interferon-alpha effectively inhibits granulocyte-macrophage colony formation in chronic myeloid leukemia
49. Effect of retinoic acid and interferon alpha on granulocyte-macrophage colony-forming cells in chronic myeloid leukemia: Increased inhibition by all-trans and 13-cis-retinoic acid in advanced stage disease
50. All-trans retinoic acid potentiates the inhibitory effects of interferon α on chronic myeloid leukemia progenitors in vitro
51. +Sca-1(+)) while enhancing the terminal maturation of committed granulocyte/monocyte progenitors
52. Self-renewal inhibition of acute myeloid leukemia clonogenic cells by biological inducers of differentiation
53. Suppression of in vitro maintenance of non-promyelocytic myeloid leukemia clonogenic cells by all-trans retinoic acid: Modulating effects of dihydroxylated vitamin D3, α interferon and 'stem cell factor'
54. A pilot study of all-trans retinoic acid in patients with Philadelphia chromosome-positive chronic myelogenous leukemia
55. All-trans retinoic acid (ATRA) in patients with chronic myeloid leukemia in the chronic phase
56. The effects of 13-cis retinoic acid and interferon alpha in chronic myelogenous leukemia cells in vivo in patients
57. Pharmacokinetic studies of 13-cis-retinoic acid in pediatric patients with neuroblastoma following bone marrow transplantation